Corporate Overview

Uroplasty, Inc., (AMEX: UPI) provides essential solutions for incontinence. The company's focus is on clinically effective, minimally-invasive therapies that may be performed in an office-based or outpatient setting. These therapies deliver significant improvement in quality of life for patients and provide physicians unique products to broaden the treatment options for patients within their incontinence practices.

• Urgent^® PC Neuromodulation System is a simple, office-based product for treatment for urinary urgency, urinary frequency and urge incontinence. In the U.S. alone, more than 35 million individuals have one or more of these symptoms. Outside the United States Urgent PC is also indicated for the treatment of faecal incontinence.
• Macroplastique^® Implants are now globally available to treat adult female stress urinary incontinence (SUI). Macroplastique is also CE marked for vesicoureteral reflux & male SUI. Used internationally for 15 years and on more than 60,000 patients, it is the predictable, permanent, and proven urethral bulking solution.
  

Essential Uroplasty News

Feb 1, 2010 - Uroplasty Reports Results For Third Quarter Fy2010

Jan 20, 2010 - Uroplasty To Issue Third Fiscal Quarter Results On February 1 2010

Dec 10, 2009 - Orbit Study Long Term Results Show Sustained Theraputic Effect Of Percutaneous Tibial Nerve Stimulation At 12 Months

> More News

Upcoming Events
> Events Calendar